Skip to main content
NCBI home page
Journal of Psychiatry & Neuroscience: JPN logoLink to Journal of Psychiatry & Neuroscience: JPN
. 1999 Jan;24(1):15–24.

Obsessive-compulsive disorder in schizophrenia: epidemiologic and biologic overlap.

P Tibbo 1, L Warneke 1
PMCID: PMC1188973  PMID: 9987204

Abstract

OBJECTIVE: To examine the co-existence of obsessive-compulsive disorder (OCD) with schizophrenia in terms of epidemiology and overlapping biologic substrates. METHODS: Review of the relevant literature. RESULTS: There appears to be a significant prevalence of OCD in schizophrenia--higher than what would be expected on the basis of calculated comorbidity figures. There is significant overlap in the proposed functional circuits of OCD and schizophrenia, which may lead to co-expression of symptoms. Although there is overlap in neurotransmitter dysfunction, the interactions are complex, especially in regard to the serotonin and dopamine systems. CONCLUSION: The expression of OCD in schizophrenia is complex but very intriguing. Theoretical hypotheses of the pathology of the 2 disorders now need to be tested in larger controlled trials.

Full text

PDF
15

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abi-Dargham A., Laruelle M., Aghajanian G. K., Charney D., Krystal J. The role of serotonin in the pathophysiology and treatment of schizophrenia. J Neuropsychiatry Clin Neurosci. 1997 Winter;9(1):1–17. doi: 10.1176/jnp.9.1.1. [DOI] [PubMed] [Google Scholar]
  2. Adams B. L., Warneke L. B., McEwan A. J., Fraser B. A. Single photon emission computerized tomography in obsessive compulsive disorder: a preliminary study. J Psychiatry Neurosci. 1993 May;18(3):109–112. [PMC free article] [PubMed] [Google Scholar]
  3. Alexander G. E., Crutcher M. D., DeLong M. R. Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions. Prog Brain Res. 1990;85:119–146. [PubMed] [Google Scholar]
  4. Alexander G. E., Crutcher M. D. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci. 1990 Jul;13(7):266–271. doi: 10.1016/0166-2236(90)90107-l. [DOI] [PubMed] [Google Scholar]
  5. Alexander G. E., DeLong M. R., Strick P. L. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci. 1986;9:357–381. doi: 10.1146/annurev.ne.09.030186.002041. [DOI] [PubMed] [Google Scholar]
  6. Allen L., Tejera C. Treatment of clozapine-induced obsessive-compulsive symptoms with sertraline. Am J Psychiatry. 1994 Jul;151(7):1096–1097. doi: 10.1176/ajp.151.7.1096b. [DOI] [PubMed] [Google Scholar]
  7. Alzaid K., Jones B. D. A case report of risperidone-induced obsessive-compulsive symptoms. J Clin Psychopharmacol. 1997 Feb;17(1):58–59. doi: 10.1097/00004714-199702000-00014. [DOI] [PubMed] [Google Scholar]
  8. Andreasen N. C., Arndt S., Swayze V., 2nd, Cizadlo T., Flaum M., O'Leary D., Ehrhardt J. C., Yuh W. T. Thalamic abnormalities in schizophrenia visualized through magnetic resonance image averaging. Science. 1994 Oct 14;266(5183):294–298. doi: 10.1126/science.7939669. [DOI] [PubMed] [Google Scholar]
  9. Andreasen N. C., Ehrhardt J. C., Swayze V. W., 2nd, Alliger R. J., Yuh W. T., Cohen G., Ziebell S. Magnetic resonance imaging of the brain in schizophrenia. The pathophysiologic significance of structural abnormalities. Arch Gen Psychiatry. 1990 Jan;47(1):35–44. doi: 10.1001/archpsyc.1990.01810130037006. [DOI] [PubMed] [Google Scholar]
  10. Andreasen N. C. The role of the thalamus in schizophrenia. Can J Psychiatry. 1997 Feb;42(1):27–33. doi: 10.1177/070674379704200104. [DOI] [PubMed] [Google Scholar]
  11. Arnt J., Hyttel J. Facilitation of 8-OHDPAT-induced forepaw treading of rats by the 5-HT2 agonist DOI. Eur J Pharmacol. 1989 Feb 14;161(1):45–51. doi: 10.1016/0014-2999(89)90178-7. [DOI] [PubMed] [Google Scholar]
  12. Backus L. I., Sharp T., Grahame-Smith D. G. Behavioural evidence for a functional interaction between central 5-HT2 and 5-HT1A receptors. Br J Pharmacol. 1990 Aug;100(4):793–799. doi: 10.1111/j.1476-5381.1990.tb14094.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Baker R. W., Ames D., Umbricht D. S., Chengappa K. N., Schooler N. R. Obsessive-compulsive symptoms in schizophrenia: a comparison of olanzapine and placebo. Psychopharmacol Bull. 1996;32(1):89–93. [PubMed] [Google Scholar]
  14. Baker R. W., Chengappa K. N., Baird J. W., Steingard S., Christ M. A., Schooler N. R. Emergence of obsessive compulsive symptoms during treatment with clozapine. J Clin Psychiatry. 1992 Dec;53(12):439–442. [PubMed] [Google Scholar]
  15. Baxter L. R., Jr, Phelps M. E., Mazziotta J. C., Guze B. H., Schwartz J. M., Selin C. E. Local cerebral glucose metabolic rates in obsessive-compulsive disorder. A comparison with rates in unipolar depression and in normal controls. Arch Gen Psychiatry. 1987 Mar;44(3):211–218. doi: 10.1001/archpsyc.1987.01800150017003. [DOI] [PubMed] [Google Scholar]
  16. Baxter L. R., Jr, Schwartz J. M., Bergman K. S., Szuba M. P., Guze B. H., Mazziotta J. C., Alazraki A., Selin C. E., Ferng H. K., Munford P. Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. Arch Gen Psychiatry. 1992 Sep;49(9):681–689. doi: 10.1001/archpsyc.1992.01820090009002. [DOI] [PubMed] [Google Scholar]
  17. Berman I., Kalinowski A., Berman S. M., Lengua J., Green A. I. Obsessive and compulsive symptoms in chronic schizophrenia. Compr Psychiatry. 1995 Jan-Feb;36(1):6–10. doi: 10.1016/0010-440x(95)90092-a. [DOI] [PubMed] [Google Scholar]
  18. Berrios G. E. Obsessive-compulsive disorder: its conceptual history in France during the 19th century. Compr Psychiatry. 1989 Jul-Aug;30(4):283–295. doi: 10.1016/0010-440x(89)90052-7. [DOI] [PubMed] [Google Scholar]
  19. Birnie W. A., Littmann S. K. Obsessionality and schizophrenia. Can Psychiatr Assoc J. 1978 Mar;23(2):77–81. doi: 10.1177/070674377802300202. [DOI] [PubMed] [Google Scholar]
  20. Bland R. C., Newman S. C., Orn H. Schizophrenia: lifetime co-morbidity in a community sample. Acta Psychiatr Scand. 1987 Apr;75(4):383–391. doi: 10.1111/j.1600-0447.1987.tb02806.x. [DOI] [PubMed] [Google Scholar]
  21. Blier P., Serrano A., Scatton B. Differential responsiveness of the rat dorsal and median raphe 5-HT systems to 5-HT1 receptor agonists and p-chloroamphetamine. Synapse. 1990;5(2):120–133. doi: 10.1002/syn.890050206. [DOI] [PubMed] [Google Scholar]
  22. Buchsbaum M. S., Haier R. J., Potkin S. G., Nuechterlein K., Bracha H. S., Katz M., Lohr J., Wu J., Lottenberg S., Jerabek P. A. Frontostriatal disorder of cerebral metabolism in never-medicated schizophrenics. Arch Gen Psychiatry. 1992 Dec;49(12):935–942. doi: 10.1001/archpsyc.1992.01820120023005. [DOI] [PubMed] [Google Scholar]
  23. Buckley P. F., Sajatovic M., Meltzer H. Y. Treatment of delusional disorders with clozapine. Am J Psychiatry. 1994 Sep;151(9):1394–1395. doi: 10.1176/ajp.151.9.1394. [DOI] [PubMed] [Google Scholar]
  24. Cassady S. L., Thaker G. K. Addition of fluoxetine to clozapine. Am J Psychiatry. 1992 Sep;149(9):1274–1274. [PubMed] [Google Scholar]
  25. Cowen P. J., Charig E. M. Neuroendocrine responses to intravenous tryptophan in major depression. Arch Gen Psychiatry. 1987 Nov;44(11):958–966. doi: 10.1001/archpsyc.1987.01800230038008. [DOI] [PubMed] [Google Scholar]
  26. Cummings J. L. Frontal-subcortical circuits and human behavior. Arch Neurol. 1993 Aug;50(8):873–880. doi: 10.1001/archneur.1993.00540080076020. [DOI] [PubMed] [Google Scholar]
  27. Dewey S. L., Smith G. S., Logan J., Alexoff D., Ding Y. S., King P., Pappas N., Brodie J. D., Ashby C. R., Jr Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis. J Neurosci. 1995 Jan;15(1 Pt 2):821–829. doi: 10.1523/JNEUROSCI.15-01-00821.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Deymeer F., Smith T. W., DeGirolami U., Drachman D. A. Thalamic dementia and motor neuron disease. Neurology. 1989 Jan;39(1):58–61. doi: 10.1212/wnl.39.1.58. [DOI] [PubMed] [Google Scholar]
  29. Dodt J. E., Byerly M. J., Cuadros C., Christensen R. C. Treatment of risperidone-induced obsessive-compulsive symptoms with sertraline. Am J Psychiatry. 1997 Apr;154(4):582–582. doi: 10.1176/ajp.154.4.582a. [DOI] [PubMed] [Google Scholar]
  30. Dominguez R. A., Jacobson A. F., de la Gandara J., Goldstein B. J., Steinbook R. M. Drug response assessed by the Modified Maudsley Obsessive-Compulsive Inventory. Psychopharmacol Bull. 1989;25(2):215–218. [PubMed] [Google Scholar]
  31. Dursun S. M., Reveley M. A. Obsessive-compulsive symptoms and clozapine. Br J Psychiatry. 1994 Aug;165(2):267–268. doi: 10.1192/bjp.165.2.267. [DOI] [PubMed] [Google Scholar]
  32. Eales M. J., Layeni A. O. Exacerbation of obsessive-compulsive symptoms associated with clozapine. Br J Psychiatry. 1994 May;164(5):687–688. doi: 10.1192/bjp.164.5.687. [DOI] [PubMed] [Google Scholar]
  33. Eisen J. L., Beer D. A., Pato M. T., Venditto T. A., Rasmussen S. A. Obsessive-compulsive disorder in patients with schizophrenia or schizoaffective disorder. Am J Psychiatry. 1997 Feb;154(2):271–273. doi: 10.1176/ajp.154.2.271. [DOI] [PubMed] [Google Scholar]
  34. Eisen J. L., Rasmussen S. A. Obsessive compulsive disorder with psychotic features. J Clin Psychiatry. 1993 Oct;54(10):373–379. [PubMed] [Google Scholar]
  35. Eison A. S., Yocca F. D. Reduction in cortical 5HT2 receptor sensitivity after continuous gepirone treatment. Eur J Pharmacol. 1985 May 20;111(3):389–392. doi: 10.1016/0014-2999(85)90648-x. [DOI] [PubMed] [Google Scholar]
  36. Fenton W. S., McGlashan T. H. The prognostic significance of obsessive-compulsive symptoms in schizophrenia. Am J Psychiatry. 1986 Apr;143(4):437–441. doi: 10.1176/ajp.143.4.437. [DOI] [PubMed] [Google Scholar]
  37. Flaum M., Swayze V. W., 2nd, O'Leary D. S., Yuh W. T., Ehrhardt J. C., Arndt S. V., Andreasen N. C. Effects of diagnosis, laterality, and gender on brain morphology in schizophrenia. Am J Psychiatry. 1995 May;152(5):704–714. doi: 10.1176/ajp.152.5.704. [DOI] [PubMed] [Google Scholar]
  38. GORDON A. Transition of obsessions into delusions. Evaluation of obsessional phenomena from the prognostic standpoint. Am J Psychiatry. 1950 Dec;107(6):455–458. doi: 10.1176/ajp.107.6.455. [DOI] [PubMed] [Google Scholar]
  39. Ghaemi S. N., Zarate C. A., Jr, Popli A. P., Pillay S. S., Cole J. O. Is there a relationship between clozapine and obsessive-compulsive disorder?: a retrospective chart review. Compr Psychiatry. 1995 Jul-Aug;36(4):267–270. doi: 10.1016/s0010-440x(95)90071-3. [DOI] [PubMed] [Google Scholar]
  40. Glennon R. A., Darmani N. A., Martin B. R. Multiple populations of serotonin receptors may modulate the behavioral effects of serotonergic agents. Life Sci. 1991;48(26):2493–2498. doi: 10.1016/0024-3205(91)90603-9. [DOI] [PubMed] [Google Scholar]
  41. Goodman W. K., McDougle C. J., Price L. H. The role of serotonin and dopamine in the pathophysiology of obsessive compulsive disorder. Int Clin Psychopharmacol. 1992 Jun;7 (Suppl 1):35–38. doi: 10.1097/00004850-199206001-00009. [DOI] [PubMed] [Google Scholar]
  42. Goodman W. K., Price L. H., Rasmussen S. A., Mazure C., Fleischmann R. L., Hill C. L., Heninger G. R., Charney D. S. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry. 1989 Nov;46(11):1006–1011. doi: 10.1001/archpsyc.1989.01810110048007. [DOI] [PubMed] [Google Scholar]
  43. Grimsley S. R., Jann M. W. Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors. Clin Pharm. 1992 Nov;11(11):930–957. [PubMed] [Google Scholar]
  44. Groenewegen H. J., Berendse H. W., Wolters J. G., Lohman A. H. The anatomical relationship of the prefrontal cortex with the striatopallidal system, the thalamus and the amygdala: evidence for a parallel organization. Prog Brain Res. 1990;85:95–118. doi: 10.1016/s0079-6123(08)62677-1. [DOI] [PubMed] [Google Scholar]
  45. Haut M. W., Cahill J., Cutlip W. D., Stevenson J. M., Makela E. H., Bloomfield S. M. On the nature of Wisconsin Card Sorting Test performance in schizophrenia. Psychiatry Res. 1996 Nov 1;65(1):15–22. doi: 10.1016/0165-1781(96)02940-x. [DOI] [PubMed] [Google Scholar]
  46. Hoyer D., Pazos A., Probst A., Palacios J. M. Serotonin receptors in the human brain. II. Characterization and autoradiographic localization of 5-HT1C and 5-HT2 recognition sites. Brain Res. 1986 Jun 18;376(1):97–107. doi: 10.1016/0006-8993(86)90903-0. [DOI] [PubMed] [Google Scholar]
  47. KRINGLEN E. OBSESSIONAL NEUROTICS: A LONG-TERM FOLLOW-UP. Br J Psychiatry. 1965 Aug;111:709–722. doi: 10.1192/bjp.111.477.709. [DOI] [PubMed] [Google Scholar]
  48. Karno M., Golding J. M., Sorenson S. B., Burnam M. A. The epidemiology of obsessive-compulsive disorder in five US communities. Arch Gen Psychiatry. 1988 Dec;45(12):1094–1099. doi: 10.1001/archpsyc.1988.01800360042006. [DOI] [PubMed] [Google Scholar]
  49. Kellner C. H., Jolley R. R., Holgate R. C., Austin L., Lydiard R. B., Laraia M., Ballenger J. C. Brain MRI in obsessive-compulsive disorder. Psychiatry Res. 1991 Jan;36(1):45–49. doi: 10.1016/0165-1781(91)90116-7. [DOI] [PubMed] [Google Scholar]
  50. Kopala L., Honer W. G. Risperidone, serotonergic mechanisms, and obsessive-compulsive symptoms in schizophrenia. Am J Psychiatry. 1994 Nov;151(11):1714–1715. doi: 10.1176/ajp.151.11.1714a. [DOI] [PubMed] [Google Scholar]
  51. Laird L. K. Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder. Psychopharmacol Bull. 1996;32(4):569–578. [PubMed] [Google Scholar]
  52. Levkovitch Y., Kronnenberg Y., Gaoni B. Can clozapine trigger OCD? J Am Acad Child Adolesc Psychiatry. 1995 Mar;34(3):263–263. doi: 10.1097/00004583-199503000-00005. [DOI] [PubMed] [Google Scholar]
  53. Lewis A. Problems of Obsessional Illness: (Section of Psychiatry). Proc R Soc Med. 1936 Feb;29(4):325–336. doi: 10.1177/003591573602900418. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Leysen J. E., Janssen P. M., Schotte A., Luyten W. H., Megens A. A. Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors. Psychopharmacology (Berl) 1993;112(1 Suppl):S40–S54. doi: 10.1007/BF02245006. [DOI] [PubMed] [Google Scholar]
  55. Lo W. H. A follow-up study of obsessional neurotics in Hong Kong Chinese. Br J Psychiatry. 1967 Aug;113(501):823–832. doi: 10.1192/bjp.113.501.823. [DOI] [PubMed] [Google Scholar]
  56. Luxenberg J. S., Swedo S. E., Flament M. F., Friedland R. P., Rapoport J., Rapoport S. I. Neuroanatomical abnormalities in obsessive-compulsive disorder detected with quantitative X-ray computed tomography. Am J Psychiatry. 1988 Sep;145(9):1089–1093. doi: 10.1176/ajp.145.9.1089. [DOI] [PubMed] [Google Scholar]
  57. Martinot J. L., Allilaire J. F., Mazoyer B. M., Hantouche E., Huret J. D., Legaut-Demare F., Deslauriers A. G., Hardy P., Pappata S., Baron J. C. Obsessive-compulsive disorder: a clinical, neuropsychological and positron emission tomography study. Acta Psychiatr Scand. 1990 Sep;82(3):233–242. doi: 10.1111/j.1600-0447.1990.tb03059.x. [DOI] [PubMed] [Google Scholar]
  58. Mindus, Jenike M. A. Neurosurgical treatment of malignant obsessive compulsive disorder. Psychiatr Clin North Am. 1992 Dec;15(4):921–938. [PubMed] [Google Scholar]
  59. Modell J. G., Mountz J. M., Curtis G. C., Greden J. F. Neurophysiologic dysfunction in basal ganglia/limbic striatal and thalamocortical circuits as a pathogenetic mechanism of obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci. 1989 Winter;1(1):27–36. doi: 10.1176/jnp.1.1.27. [DOI] [PubMed] [Google Scholar]
  60. Molliver M. E. Serotonergic neuronal systems: what their anatomic organization tells us about function. J Clin Psychopharmacol. 1987 Dec;7(6 Suppl):3S–23S. [PubMed] [Google Scholar]
  61. Moossy J., Martinez A. J., Hanin I., Rao G., Yonas H., Boller F. Thalamic and subcortical gliosis with dementia. Arch Neurol. 1987 May;44(5):510–513. doi: 10.1001/archneur.1987.00520170040019. [DOI] [PubMed] [Google Scholar]
  62. Mozes T., Toren P., Chernauzan N., Mester R., Yoran-Hegesh R., Blumensohn R., Weizman A. Clozapine treatment in very early onset schizophrenia. J Am Acad Child Adolesc Psychiatry. 1994 Jan;33(1):65–70. doi: 10.1097/00004583-199401000-00010. [DOI] [PubMed] [Google Scholar]
  63. Olpe H. R., Koella W. P. The response of striatal cells upon stimulation of the dorsal and median raphe nuclei. Brain Res. 1977 Feb 18;122(2):357–360. doi: 10.1016/0006-8993(77)90302-x. [DOI] [PubMed] [Google Scholar]
  64. POLLITT J. Natural history of obsessional states; a study of 150 cases. Br Med J. 1957 Jan 26;1(5012):194–198. doi: 10.1136/bmj.1.5012.194. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Parent A. Extrinsic connections of the basal ganglia. Trends Neurosci. 1990 Jul;13(7):254–258. doi: 10.1016/0166-2236(90)90105-j. [DOI] [PubMed] [Google Scholar]
  66. Parkin A. Neurosis and schizophrenia. II. Modern perspectives. Psychiatr Q. 1966 Apr;40(2):217–235. doi: 10.1007/BF01562755. [DOI] [PubMed] [Google Scholar]
  67. Patel B., Tandon R. Development of obsessive-compulsive symptoms during clozapine treatment. Am J Psychiatry. 1993 May;150(5):836–836. doi: 10.1176/ajp.150.5.836a. [DOI] [PubMed] [Google Scholar]
  68. Patil V. J. Development of transient obsessive-compulsive symptoms during treatment with clozapine. Am J Psychiatry. 1992 Feb;149(2):272–272. doi: 10.1176/ajp.149.2.272a. [DOI] [PubMed] [Google Scholar]
  69. Pitman R. K., Green R. C., Jenike M. A., Mesulam M. M. Clinical comparison of Tourette's disorder and obsessive-compulsive disorder. Am J Psychiatry. 1987 Sep;144(9):1166–1171. doi: 10.1176/ajp.144.9.1166. [DOI] [PubMed] [Google Scholar]
  70. ROSEN I. The clinical significance of obsessions in schizophrenia. J Ment Sci. 1957 Oct;103(433):773–785. doi: 10.1192/bjp.103.433.773. [DOI] [PubMed] [Google Scholar]
  71. Rapoport J. L., Wise S. P. Obsessive-compulsive disorder: evidence for basal ganglia dysfunction. Psychopharmacol Bull. 1988;24(3):380–384. [PubMed] [Google Scholar]
  72. Rauch S. L., Jenike M. A., Alpert N. M., Baer L., Breiter H. C., Savage C. R., Fischman A. J. Regional cerebral blood flow measured during symptom provocation in obsessive-compulsive disorder using oxygen 15-labeled carbon dioxide and positron emission tomography. Arch Gen Psychiatry. 1994 Jan;51(1):62–70. doi: 10.1001/archpsyc.1994.03950010062008. [DOI] [PubMed] [Google Scholar]
  73. Remington G., Adams M. Risperidone and obsessive-compulsive symptoms. J Clin Psychopharmacol. 1994 Oct;14(5):358–359. doi: 10.1097/00004714-199410000-00014. [DOI] [PubMed] [Google Scholar]
  74. Rosenberg C. M. Complications of obsessional neurosis. Br J Psychiatry. 1968 Apr;114(509):477–478. doi: 10.1192/bjp.114.509.477. [DOI] [PubMed] [Google Scholar]
  75. Saxena S., Wang D., Bystritsky A., Baxter L. R., Jr Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry. 1996 Jul;57(7):303–306. [PubMed] [Google Scholar]
  76. Seidman L. J., Yurgelun-Todd D., Kremen W. S., Woods B. T., Goldstein J. M., Faraone S. V., Tsuang M. T. Relationship of prefrontal and temporal lobe MRI measures to neuropsychological performance in chronic schizophrenia. Biol Psychiatry. 1994 Feb 15;35(4):235–246. doi: 10.1016/0006-3223(94)91254-8. [DOI] [PubMed] [Google Scholar]
  77. Stanley J. A., Williamson P. C., Drost D. J., Carr T. J., Rylett R. J., Malla A., Thompson R. T. An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy. Arch Gen Psychiatry. 1995 May;52(5):399–406. doi: 10.1001/archpsyc.1995.03950170073010. [DOI] [PubMed] [Google Scholar]
  78. Swedo S. E., Pietrini P., Leonard H. L., Schapiro M. B., Rettew D. C., Goldberger E. L., Rapoport S. I., Rapoport J. L., Grady C. L. Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder. Revisualization during pharmacotherapy. Arch Gen Psychiatry. 1992 Sep;49(9):690–694. doi: 10.1001/archpsyc.1992.01820090018003. [DOI] [PubMed] [Google Scholar]
  79. Talairach J., Bancaud J., Geier S., Bordas-Ferrer M., Bonis A., Szikla G., Rusu M. The cingulate gyrus and human behaviour. Electroencephalogr Clin Neurophysiol. 1973 Jan;34(1):45–52. doi: 10.1016/0013-4694(73)90149-1. [DOI] [PubMed] [Google Scholar]
  80. Thomsen P. H., Jensen J. Obsessive-compulsive disorder: admission patterns and diagnostic stability. A case-register study. Acta Psychiatr Scand. 1994 Jul;90(1):19–24. doi: 10.1111/j.1600-0447.1994.tb01550.x. [DOI] [PubMed] [Google Scholar]
  81. Toren P., Samuel E., Weizman R., Golomb A., Eldar S., Laor N. Case study: emergence of transient compulsive symptoms during treatment with clothiapine. J Am Acad Child Adolesc Psychiatry. 1995 Nov;34(11):1469–1472. [PubMed] [Google Scholar]
  82. Welner A., Reich T., Robins E., Fishman R., Van Doren T. Obsessive-compulsive neurosis: record, follow-up, and family studies. I. Inpatient record study. Compr Psychiatry. 1976 Jul-Aug;17(4):527–539. doi: 10.1016/0010-440x(76)90035-3. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Psychiatry and Neuroscience are provided here courtesy of Canadian Science Publishing

RESOURCES